Medicare Bundling Provisions Could Boost Affymax ESA in ESRD Arena
Executive Summary
Affymax sees the end-stage renal disease treatment bundling provisions in the Medicare Improvements for Patients and Providers Act as a potential opportunity for its new erythropoiesis stimulating agent to pull market share from Amgen's Epogen